Better Therapeutics Enrolls First Patient in Real-World Evidence Study with Catalyst Health Network Evaluating BT-001, a Prescription Digital Therapeutic for Type 2 Diabetes

SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, in collaboration with Catalyst Health Network (“Catalyst”), today announced the first patient has been enrolled in a real-world evidence study to evaluate the long-term effectiveness and...

Click to view original post